Coherus Medical, a biotech developing knockoffs of some of the world's top-selling treatments, is plotting an $86 million IPO to bankroll its late-stage R&D work.
Takeda Pharmaceutical has stepped up with a $25 million investment in Cleveland's BioMotiv, buying into the accelerator's promise to transform academic discoveries into market-bound therapeutics.
Gilead Sciences, already a trailblazer in hepatitis C treatment, is creeping up on its next milestone: approval for a combination therapy that promises to cure the majority of patients without the need for painful injections.
Pharmacyclics and Servier are quietly walking away from a 5-year collaboration on a new cancer treatment, leaving the former company to go it alone on mid-stage oral drug with an uncertain future.
Novo Nordisk has made it official: The Danish drugmaker is making a full-fledged go at obesity R&D, looking to build a Seattle hub and hire up some investigators as it expands its research palate.
German drug developer Probiodrug is looking to go public on the Amsterdam exchange, seeking funds to advance its pipeline of treatments for Alzheimer's disease as more and more European biotechs set sights on IPOs.
Welcome to the latest edition of our weekly EuroBiotech Report.
Valeant Pharmaceuticals is famous for its aversion to pharmaceutical R&D, but the serial acquirer makes an exception when it sees blockbuster promise in a late-stage asset. And that's the case for the glaucoma treatment Vesneo, which met its goals in pivotal trials and, according to the company, has blockbuster potential.
Jockeying with a slew of next-generation treatments, Novartis' new anti-inflammatory drug succeeded in two Phase III trials on patients with psoriatic arthritis, stoking the company's hopes of snagging significant market share once it wins approval.
Regado had all of its eggs in one basket when it took its lead therapy into a Phase III trial on its own. And now that the anticoagulant study has been shelved after signs of a severe allergic reaction were seen among patients, the biotech is cutting more than half of its staffers in an effort to preserve cash and review what kind of moves it can still make.
A slate of top-tier biotech investors are coming in with a whopping $104 million Series A designed to take Oxford-based Adaptimmune--named a Fierce 15 company earlier in the week--well down the clinical path on its immuno-oncology tech.
Back at the beginning of this month, Seattle-based VentiRx spread the news that it had raised a venture round for its newly fast-tracked TLR8 cancer vaccine research, but didn't disclose just how much it had in hand. A new filing at the SEC, though, puts the venture figure at $50.6 million, with another $2.4 million or so left to add in the planned raise.
Gilead says that a pair of late-stage studies of its single-tablet combo therapy for HIV hit their primary endpoints, paving the way to an FDA filing later in the year.
Bristol-Myers Squibb is gearing up to build a 2,500-employee campus in New Jersey, following the biopharma trend of ditching far-flung outposts in favor of collaboration-encouraging hubs.
Lipocine is touting positive late-stage results for its testosterone replacement pill, gearing up for intense FDA scrutiny amid a sea change in how the regulator looks at so-called low-T treatments.
Eight months after partnering with Novartis, Emeryville, CA-based Eureka Therapeutics has landed a $21 million round led by a Chinese private equity firm. Beijing-based Yuan Capital led the round, with Majuven and all the current major investors, including Acorn Campus Ventures, Suma Venture and Harbinger Venture Capital, joining in.
Five years after wrapping up his prison term over an insider trading scandal, biotech veteran Sam Waksal says he's ready to take another company public, plotting a debut for Kadmon.
Acorda Therapeutics is gambling $525 million on a Phase III-ready Parkinson's treatment, striking an all-cash deal to buy Civitas Therapeutics.
With a big corporate split looming ahead, Baxter has stepped in to pick up the ex-U.S. rights to Merrimack Pharmaceuticals' lead cancer therapy, paying $100 million in an upfront fee and committing up to $870 million in additional milestones for the late-stage treatment.